ivabradine has been researched along with Chronic Disease in 78 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (14.10) | 29.6817 |
| 2010's | 59 (75.64) | 24.3611 |
| 2020's | 8 (10.26) | 2.80 |
| Authors | Studies |
|---|---|
| Baopeng, T; Caizhen, Q; Huiyuan, H; Jingmin, Z; Junbo, G; Wenhui, D; Yamei, X; Yuhui, Z | 1 |
| Amrawy, AME; Dogheim, GM; El-Haggar, SM; Khairat, I; Omran, GA; Werida, RH | 1 |
| Ako, J; Hagiwara, N; Inomata, T; Ito, H; Kawasaki, Y; Kihara, Y; Momomura, SI; Saito, Y; Sakata, Y; Shimokawa, H; Tanaka, T; Tsutsui, H; Yamamoto, K; Yamashina, A; Yano, M | 1 |
| Chen, S; Meng, Z; Peng, J; Sun, K; Wang, J; Wang, Q; Zhou, S; Zhou, Y | 1 |
| Bigelow, R; Cole, RT; DeVore, AD; Fonarow, GC; Ginwalla, M; Heitner, JF; Hernandez, AF; Lala, A; Lanfear, DD; Mentz, RJ; Old, W; Patel, CB; Piña, IL; Salacata, AS; Tasissa, G | 1 |
| Iwahana, T; Kobayashi, Y; Okada, S | 1 |
| Ide, T; Kawasaki, Y; Tsutsui, H | 1 |
| Benstoem, C; Brandenburg, V; Breuer, T; Heussen, N; Kalvelage, C; Marx, G; Stoppe, C | 1 |
| Greco, S; Guadagnino, G; Mastroianni, A; Urso, F; Vangeli, V | 1 |
| Dolatshahi, Z; Mezginejad, F; Nargesi, S; Rashki Kemmak, A | 1 |
| Stöckl, G; Störk, S; Zugck, C | 1 |
| Azeem, S; Fernando, C; Moe, GW; Roth, S | 1 |
| Böhm, M; Borer, J; Cowie, M; Komajda, M; Lainscak, M; Nikolovska Vukadinović, A; Swedberg, K; Vukadinović, D | 1 |
| Berdeaux, A; Bizé, A; Bouhemad, B; Ghaleh, B; Hittinger, L; Jozwiak, M; Melka, J; Rienzo, M; Sambin, L; Su, JB | 1 |
| Fejzic, D; Hoppe, UC; Jirak, P; Jung, C; Kretzschmar, D; Lichtenauer, M; Paar, V; Pistulli, R; Rohm, I; Schulze, PC; Wernly, B; Yilmaz, A | 1 |
| Bonadei, I; Carubelli, V; Fabbricatore, D; Lombardi, CM; Metra, M; Pagnoni, M; Rossi, L; Sciatti, E; Vizzardi, E | 1 |
| Fragasso, G; Gemma, M; Godino, C; Margonato, A; Montanaro, C; Pinto, G; Salerno, A; Slavich, M; Spoladore, R; Tondi, L | 1 |
| Chow, SL; Depre, C; Page, RL | 1 |
| Borisenko, YV; Kanorskiy, SG | 1 |
| Brugts, JJ; Brunner-La Rocca, HP; Hoes, AW; Linssen, GC; Rademaker, PC; Schaafsma, HJ; Smeele, FJ; van de Kamp, HJ; van Drimmelen, AA; Westendorp, PH | 1 |
| Böhm, M; Custodis, F; Fries, P; Hohneck, AL; Laufs, U; Schirmer, SH; Schneider, G; Ströder, J; Wagenpfeil, S | 1 |
| Lim, WY; Woldman, S | 1 |
| Abrahamsson, P; Böhm, M; Borer, JS; Ford, I; Kober, L; Komajda, M; Lloyd, SM; Metra, M; Swedberg, K; Tavazzi, L | 1 |
| Böhm, M; Borer, JS; Ford, I; Komajda, M; Lainscak, M; Swedberg, K; Tavazzi, L | 1 |
| Böhm, M; Borer, JS; Ford, I; Komajda, M; Lainscak, M; Robertson, M; Swedberg, K; Tavazzi, L | 1 |
| Benvenuto, A; Buta, F; De Viti, D; Masciocco, L; Massari, F; Meliota, G; Riccioni, G; Saracino, P; Speziale, G | 1 |
| Di Franco, A; Di Pasquale, P; Figliozzi, S; Lanza, GA; Parrinello, R; Salerno, Y; Sarullo, FM | 1 |
| Branscombe, N; Cowie, MR; Davies, A; Griffiths, A; Paracha, N; Sculpher, M | 1 |
| Martinka, P; Stöckl, G; Zugck, C | 1 |
| Maggioni, AP; Oliva, F; Polistena, B; Spandonaro, F | 1 |
| Beletsi, A; Branscombe, N; Karavidas, A; Kourlaba, G; Maniadakis, N; Milonas, C; Parissis, J | 1 |
| Charles, H; Cochrane, L; Elder, DH; Lang, CC; Mohan, M | 1 |
| Traynor, K | 1 |
| Borer, JS; Ford, I; Kielhorn, A; Pocock, SJ; Rogers, JK | 1 |
| Nguyen, E; Weeda, ER; White, CM | 1 |
| Ako, J; Hagiwara, N; Inomata, T; Ito, H; Kawasaki, Y; Kihara, Y; Momomura, S; Ogawa, H; Saito, Y; Shimokawa, H; Tanaka, T; Tsutsui, H; Yamashina, A | 1 |
| De Denus, S; Elzir, L; Henri, C; O'Meara, E; Tardif, JC | 1 |
| Anker, SD; Cowie, MR; Filippatos, GS; Komajda, M; Mengelle, B; Ponikowski, P; Tavazzi, L | 1 |
| Al-Saadi, T; Al-Zakwani, I; Alshekaili, L; Sallam, M | 1 |
| Psotka, MA; Teerlink, JR | 1 |
| Hein, L; Lother, A | 1 |
| Khachatryan, A; Sargsyan, T; Sisakian, H | 1 |
| Hancox, JC; Melgari, D; Ng, GA | 1 |
| Cook, JC; Patterson, JH; Rodgers, JE; Tran, RH | 1 |
| Böhm, M; Borer, JS; Deedwania, PC; Kim, JB | 1 |
| Franz, M; Kretzschmar, D; Pistulli, R; Rohm, I; Schulze, PC; Stumpf, C; Yilmaz, A | 1 |
| Alfonso Manterola, F; Almenar Bonet, L; Ariza Solé, A; Arribas Ynsaurriaga, F; Bover Freire, R; Bueno, H; Coca Payeras, A; Díaz Molina, B; Evangelista Masip, A; Ferreira González, I; González Juanatey, JR; Jiménez Navarro, M; Lambert Rodríguez, JL; López de Sá, E; López Fernández, S; Manito Lorite, N; Marin Ortuño, F; Martín Asenjo, R; Mirabet Pérez, S; Pascual Figal, D; Pérez de Isla, L; Rodríguez Padial, L; Ruilope Urioste, LM; San Román Calvar, JA; Sánchez Fernández, PL; Segovia Cubero, J; Sionis Green, A; Sionis, A; Varela Román, A; Vázquez García, R; Zamorano Gómez, JL | 1 |
| Müller-Werdan, U; Stöckl, G; Werdan, K | 1 |
| Kanorskiy, SG; Pokrovskiy, VM; Tregubov, VG | 1 |
| Arora, R; Jawad, E | 1 |
| Stieber, J | 1 |
| Gray, D; Prasad, UK; Purcell, H | 1 |
| de Silva, R; Fox, KM | 1 |
| Böhm, M; Borer, JS; Ford, I; Komajda, M; Swedberg, K; Tavazzi, L | 1 |
| Böhm, M; Borer, JS; Dubost-Brama, A; Ford, I; Komajda, M; Lerebours, G; Swedberg, K; Tavazzi, L | 2 |
| Di Pasquale, P; Fasullo, S; Fazio, G; Novo, S; Paterna, S; Puccio, D; Sarullo, FM | 1 |
| Hong, N; Kang, SM; Oh, J; Won, H | 1 |
| Gupta, A; Sharma, YP | 1 |
| Komajda, M | 1 |
| Hoppe, UC | 1 |
| Böhm, M; Borer, JS; Chassany, O; Ekman, I; Ford, I; Komajda, M; Swedberg, K; Tavazzi, L | 1 |
| Clark, AL; Cleland, JG; Cullington, D; Goode, KM | 1 |
| Kanorskiĭ, SG; Pokrovskiĭ, VM; Tregubov, VG | 1 |
| Ageev, FT | 1 |
| Abdulazizov, OSh; Diachuk, LI; Kiiakbaev, GK; Kobalava, ZhD; Moiseev, VS; Potapenko, AV | 1 |
| Böhm, M; Borer, J; Ford, I; Gonzalez-Juanatey, JR; Komajda, M; Lopez-Sendon, J; Reil, JC; Swedberg, K; Tavazzi, L | 1 |
| Bruhn, C | 1 |
| Alings, M; Böhm, M; Borer, JS; Ford, I; Komajda, M; Lopez-de-Sa, E; Sendon, JL; Swedberg, K; Tavazzi, L | 1 |
| Dei Cas, L; Lupi, L; Manerba, A; Nodari, S; Triggiani, M | 1 |
| Málek, F | 1 |
| Bourassa, MG; Ford, I; Fox, K; Tardif, JC; Tendera, M | 1 |
| Marber, MS; Saha, M | 1 |
| Barsness, GW; Yang, EH | 1 |
| Haghfelt, TH | 1 |
| Swedberg, K | 1 |
| Filipova, S; López-Bescós, L; Martos, R | 1 |
| Chaitman, BR; Sano, J | 1 |
22 review(s) available for ivabradine and Chronic Disease
| Article | Year |
|---|---|
Pharmacology of Ivabradine and the Effect on Chronic Heart Failure.
Topics: Animals; Cardiovascular Agents; Chronic Disease; Heart Failure; Humans; Ivabradine; Molecular Structure | 2019 |
Ivabradine as adjuvant treatment for chronic heart failure.
Topics: Bias; Cardiovascular Agents; Cardiovascular Diseases; Chemotherapy, Adjuvant; Chronic Disease; Exercise Tolerance; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Placebos; Randomized Controlled Trials as Topic; Stroke Volume | 2020 |
Economic evaluation of ivabradine in treatment of patients with heart failure: a systematic review.
Topics: Chronic Disease; Cost-Benefit Analysis; Heart Failure; Humans; Ivabradine; Quality-Adjusted Life Years | 2022 |
Heart rate and its reduction in chronic heart failure and beyond.
Topics: Benzazepines; Cardiovascular Agents; Chronic Disease; Heart Failure; Heart Rate; Humans; Ivabradine; Prognosis; Risk Factors | 2017 |
Role of ivabradine and heart rate lowering in chronic heart failure: guideline update.
Topics: Adrenergic beta-Antagonists; Benzazepines; Cardiovascular Agents; Chronic Disease; Heart Failure; Heart Failure, Systolic; Heart Rate; Hospitalization; Humans; Ivabradine; Treatment Outcome; Ventricular Dysfunction, Left | 2018 |
[Chronic Heart Failure With Preserved Ejection Fraction: Effective Treatment Possible?]
Topics: Adrenergic beta-Antagonists; Aged; Cardiovascular Agents; Chronic Disease; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2018 |
Pharmacological management of chronic heart failure: old drugs, new drugs and new indications.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cardiovascular Agents; Chronic Disease; Digoxin; Drug Combinations; Heart Failure; Heart Failure, Systolic; Humans; Hydralazine; Isosorbide Dinitrate; Ivabradine; Mineralocorticoid Receptor Antagonists | 2013 |
Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice.
Topics: Adrenergic beta-Antagonists; Benzazepines; Chronic Disease; Clinical Trials as Topic; Heart Failure; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Stroke Volume | 2014 |
A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Ivabradine; Neprilysin; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
Ivabradine for the treatment of chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Chronic Disease; Exercise Tolerance; Heart Failure; Heart Rate; Humans; Ivabradine; Quality of Life; Treatment Outcome | 2016 |
Ivabradine: Role in the Chronic Heart Failure Armamentarium.
Topics: Benzazepines; Cardiovascular Agents; Chronic Disease; Clinical Trials as Topic; Heart Failure; Hospitalization; Humans; Ivabradine | 2016 |
Pharmacology of heart failure: From basic science to novel therapies.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials as Topic; Drug Combinations; Guanylate Cyclase; Heart Failure; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Myosins; Neprilysin; Practice Guidelines as Topic; Renin-Angiotensin System; Tetrazoles; Valsartan | 2016 |
Evolving therapies for the management of chronic and acute decompensated heart failure.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials as Topic; Disease Management; Drug Combinations; Ferric Compounds; Heart Failure; Humans; Ivabradine; Maltose; Tetrazoles; Valsartan | 2016 |
Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease.
Topics: Benzazepines; Cardiovascular Agents; Chronic Disease; Coronary Artery Disease; Heart Failure, Systolic; Heart Rate; Hospitalization; Humans; Ivabradine; Mortality; Quality of Life; Treatment Outcome; Ventricular Function, Left | 2016 |
Advances in the management of heart failure: the role of ivabradine.
Topics: Action Potentials; Age Factors; Aged; Aged, 80 and over; Animals; Anti-Arrhythmia Agents; Benzazepines; Biological Clocks; Chronic Disease; Cyclic Nucleotide-Gated Cation Channels; Drug Therapy, Combination; Heart Conduction System; Heart Failure; Heart Rate; Humans; Ivabradine; Middle Aged; Patient Selection; Quality of Life; Risk Assessment; Risk Factors; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2016 |
Chronic stable angina pectoris.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetanilides; Angina Pectoris; Antihypertensive Agents; Benzazepines; Bosentan; Chronic Disease; Counterpulsation; Cyclic Nucleotide-Gated Cation Channels; Exercise Test; Heart Murmurs; Humans; Ivabradine; Myocardial Contraction; Myocardial Ischemia; Myocardial Revascularization; Myocardium; Nicorandil; Oxygen Consumption; Perhexiline; Piperazines; Protein Kinase Inhibitors; Ranolazine; Sulfonamides; Trimetazidine; Vasodilator Agents | 2008 |
Ivabradine: pharmacodynamic aspects of its clinical use.
Topics: Angina Pectoris; Animals; Benzazepines; Chronic Disease; Cyclic Nucleotide-Gated Cation Channels; Heart Rate; Humans; Ion Channels; Ivabradine | 2008 |
Review of the If selective channel inhibitor ivabradine in the treatment of chronic stable angina.
Topics: Action Potentials; Angina Pectoris; Benzazepines; Chronic Disease; Cyclic Nucleotide-Gated Cation Channels; Exercise Test; Heart Rate; Humans; Ivabradine; Membrane Transport Modulators; Patient Selection; Quality of Life; Safety; Sinoatrial Node; Treatment Outcome | 2009 |
[New therapeutic approaches in heart failure].
Topics: Adrenergic beta-Antagonists; Anemia, Iron-Deficiency; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cardiac Resynchronization Therapy; Chronic Disease; Clinical Trials as Topic; Combined Modality Therapy; Drug Therapy, Combination; Exercise Test; Heart Failure; Heart Rate; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic | 2011 |
[Ivabradine: heart rate reduction in coronary heart disease and chronic heart failure].
Topics: Benzazepines; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Drug Interactions; Heart Failure; Heart Rate; Humans; Ivabradine | 2012 |
Evolving treatment strategies for chronic refractory angina.
Topics: Acetanilides; Angina Pectoris; Arginine; Benzazepines; Cardiovascular Agents; Chronic Disease; Combined Modality Therapy; Counterpulsation; Electric Stimulation Therapy; Humans; Ivabradine; Myocardial Revascularization; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Spinal Cord | 2006 |
Novel therapeutic approaches to treating chronic angina in the setting of chronic ischemic heart disease.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Calcium Channel Blockers; Chronic Disease; Enzyme Inhibitors; Humans; Ivabradine; Myocardial Ischemia; Nicorandil; Nitro Compounds; Piperazines; Ranolazine; rho-Associated Kinases; Sinoatrial Node; Trimetazidine; Vasodilator Agents | 2007 |
23 trial(s) available for ivabradine and Chronic Disease
| Article | Year |
|---|---|
Clinical comparative study assessing the effect of ivabradine on neopterin and NT-Pro BNP against standard treatment in chronic heart failure patients.
Topics: Anti-Arrhythmia Agents; Biomarkers; Chronic Disease; Diuretics; Heart Failure; Humans; Ivabradine; Natriuretic Peptide, Brain; Neopterin; Stroke Volume | 2022 |
Efficacy and Safety of Ivabradine in Japanese Patients With Chronic Heart Failure - J-SHIFT Study.
Topics: Aged; Cardiovascular Agents; Cause of Death; Chronic Disease; Disease Progression; Double-Blind Method; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Japan; Male; Middle Aged; Patient Admission; Risk Factors; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2019 |
PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Cardiovascular Agents; Chronic Disease; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Patient Discharge | 2020 |
Effects of heart rate reduction with ivabradine on vascular stiffness and endothelial function in chronic stable coronary artery disease.
Topics: Aged; Aorta; Arterial Pressure; Brachial Artery; Cardiovascular Agents; Chronic Disease; Coronary Artery Disease; Cross-Over Studies; Double-Blind Method; Endothelium; Female; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Prospective Studies; Pulse Wave Analysis; Vascular Stiffness; Vasodilation | 2019 |
Risk following hospitalization in stable chronic systolic heart failure.
Topics: Aged; Aged, 80 and over; Benzazepines; Cardiovascular Agents; Chronic Disease; Disease Progression; Female; Follow-Up Studies; Heart Failure, Systolic; Hospitalization; Humans; Ivabradine; Male; Middle Aged; Myocardial Infarction; Prognosis; Risk Factors; Time Factors | 2013 |
Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study.
Topics: Adrenergic beta-Antagonists; Aged; Benzazepines; Cardiotonic Agents; Chronic Disease; Female; Heart Failure, Systolic; Heart Rate; Humans; Incidence; Ivabradine; Male; Middle Aged; Multivariate Analysis; Placebos; Prognosis; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Risk Factors; Treatment Outcome | 2013 |
Ivabradine improves quality of life in subjects with chronic heart failure compared to treatment with β-blockers: results of a multicentric observational APULIA study.
Topics: Adrenergic beta-Antagonists; Aged; Benzazepines; Bisoprolol; Blood Pressure; Carbazoles; Carvedilol; Chronic Disease; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Propanolamines; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2013 |
Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cardiovascular Agents; Chronic Disease; Diuretics; Drug Therapy, Combination; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Quality of Life; Treatment Outcome | 2014 |
Effect of ivabradine on numbers needed to treat for the prevention of recurrent hospitalizations in heart failure patients.
Topics: Benzazepines; Cardiovascular Agents; Chronic Disease; Heart Failure, Systolic; Heart Rate; Hospitalization; Humans; Ivabradine; Numbers Needed To Treat; Proportional Hazards Models; Treatment Outcome | 2015 |
Heart Rate Control With If Inhibitor, Ivabradine, in Japanese Patients With Chronic Heart Failure - A Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Topics: Aged; Benzazepines; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Middle Aged | 2016 |
Impact of Ivabradine on Health-Related Quality of Life of Patients with Ischaemic Chronic Heart Failure.
Topics: Adrenergic Antagonists; Aged; Benzazepines; Carbazoles; Cardiovascular Agents; Carvedilol; Chronic Disease; Drug Therapy, Combination; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Oman; Propanolamines; Prospective Studies; Quality of Life; Stroke Volume; Surveys and Questionnaires; Time Factors; Treatment Outcome; Ventricular Function, Left | 2016 |
Effect of selective heart rate reduction through sinus node I
Topics: Aged; Benzazepines; Cardiovascular Agents; Chronic Disease; Cyclic Nucleotide-Gated Cation Channels; Echocardiography, Doppler, Pulsed; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Pulse Wave Analysis; Severity of Illness Index; Sinoatrial Node; Treatment Outcome; Ventricular Dysfunction, Left | 2016 |
Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT).
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Benzazepines; Chronic Disease; Clinical Protocols; Data Collection; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Ivabradine; Male | 2010 |
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
Topics: Adult; Aged; Benzazepines; Cardiovascular Agents; Chronic Disease; Double-Blind Method; Electrocardiography; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Kaplan-Meier Estimate; Male; Middle Aged; Risk Factors; Severity of Illness Index; Sinoatrial Node; Treatment Outcome | 2010 |
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
Topics: Adult; Aged; Benzazepines; Cardiovascular Agents; Chronic Disease; Double-Blind Method; Electrocardiography; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Kaplan-Meier Estimate; Male; Middle Aged; Severity of Illness Index; Sinoatrial Node; Treatment Outcome | 2010 |
Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure.
Topics: Adrenergic beta-Antagonists; Benzazepines; Chronic Disease; Exercise; Exercise Test; Exercise Tolerance; Female; Heart Failure; Heart Rate; Humans; Ivabradine; Male; Neurotransmitter Agents; Off-Label Use; Oxygen Consumption; Quality of Life | 2010 |
Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzazepines; Cause of Death; Chronic Disease; Double-Blind Method; Female; Heart Failure, Systolic; Humans; Ivabradine; Male; Middle Aged; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2011 |
[Alternative therapy with ivabradine in patients with functional class III chronic heart failure].
Topics: Benzazepines; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cardiovascular Agents; Chronic Disease; Drug Monitoring; Drug Therapy, Combination; Echocardiography; Exercise Tolerance; Female; Heart Failure; Heart Rate; Humans; Hypertension; Ivabradine; Male; Middle Aged; Natriuretic Peptide, Brain; Oxygen Consumption; Peptide Fragments; Severity of Illness Index; Treatment Outcome | 2011 |
[Efficacy of ivabradin in combined treatment of patients with postinfarction systolic chronic cardiac failure].
Topics: Anti-Arrhythmia Agents; Benzazepines; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Treatment Outcome | 2011 |
Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study.
Topics: Aged; Anti-Arrhythmia Agents; Benzazepines; Chronic Disease; Disease Progression; Double-Blind Method; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Ivabradine; Kaplan-Meier Estimate; Male; Middle Aged; Patient Selection; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2013 |
Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study.
Topics: Benzazepines; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Female; Heart Failure, Systolic; Hospitalization; Humans; Ivabradine; Male; Middle Aged; Secondary Prevention; Treatment Outcome | 2012 |
Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Benzazepines; Cardiovascular Agents; Chronic Disease; Double-Blind Method; Exercise Tolerance; Female; Heart Conduction System; Humans; Ion Channels; Ivabradine; Male; Middle Aged | 2005 |
Long-term safety and efficacy of ivabradine in patients with chronic stable angina.
Topics: Aged; Angina Pectoris; Benzazepines; Cardiovascular Agents; Chronic Disease; Double-Blind Method; Female; Humans; Ivabradine; Male; Middle Aged; Treatment Outcome | 2007 |
33 other study(ies) available for ivabradine and Chronic Disease
| Article | Year |
|---|---|
Real-World Effectiveness of Ivabradine in Chinese Patients with Chronic Heart Failure: Interim Analysis of the POSITIVE Study.
Topics: Adult; Benzazepines; Cardiovascular Agents; China; Chronic Disease; Heart Failure; Heart Rate; Humans; Ivabradine; Prospective Studies; Quality of Life; Treatment Outcome; Ventricular Function, Left | 2022 |
Is High Heart Rate Always Harmful to Heart Failure Patients?
Topics: Chronic Disease; Heart Failure; Heart Rate; Humans; Ivabradine; Japan | 2020 |
Is High Heart Rate Always Harmful to Heart Failure Patients? - Reply.
Topics: Chronic Disease; Heart Failure; Heart Rate; Humans; Ivabradine; Japan | 2020 |
Efficacy of ivabradine in HIV-associated dilated cardiomyopathy.
Topics: Adult; Benzazepines; Cardiomyopathy, Dilated; Chronic Disease; Heart Failure; Heart Rate; HIV Infections; Humans; Ivabradine; Stroke Volume; Treatment Outcome | 2021 |
Long-term treatment with ivabradine over 12months in patients with chronic heart failure in clinical practice: Effect on symptoms, quality of life and hospitalizations.
Topics: Aged; Benzazepines; Cardiovascular Agents; Chronic Disease; Cohort Studies; Drug Administration Schedule; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Ivabradine; Male; Middle Aged; Prospective Studies; Quality of Life; Time Factors; Treatment Outcome | 2017 |
Is There a Role for Ivabradine in the Contemporary Management of Patients with Chronic Heart Failure in Academic and Community Heart Failure Clinics in Canada?
Topics: Academic Medical Centers; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Benzazepines; Canada; Chronic Disease; Drug Therapy, Combination; Female; Heart Failure; Heart Rate; Hospitals, Community; Humans; Ivabradine; Male; Middle Aged; Risk Factors; Stroke Volume; Treatment Outcome | 2017 |
Ivabradine improves left ventricular twist and untwist during chronic hypertension.
Topics: Animals; Benzazepines; Cardiovascular Agents; Chronic Disease; Female; Hypertension; Hypertrophy, Left Ventricular; Ivabradine; Swine; Ventricular Dysfunction, Left | 2018 |
Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure.
Topics: Adult; Aged; Aged, 80 and over; Benzazepines; Biomarkers; Chronic Disease; Fatty Acid Binding Protein 3; Growth Differentiation Factor 15; Heart Failure; Humans; Ivabradine; Middle Aged; Receptors, Somatostatin; Receptors, Urokinase Plasminogen Activator; Young Adult | 2018 |
Effects of ivabradine on endothelial function, aortic properties and ventricular-arterial coupling in chronic systolic heart failure patients.
Topics: Aged; Aged, 80 and over; Aorta; Benzazepines; Cardiotonic Agents; Chronic Disease; Echocardiography; Endothelium, Vascular; Female; Heart Failure, Systolic; Heart Ventricles; Humans; Ivabradine; Male; Middle Aged; Vascular Stiffness; Ventricular Remodeling | 2018 |
Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Cardiovascular Agents; Chronic Disease; Echocardiography; Female; Heart Failure, Systolic; Heart Rate; Hospitalization; Humans; Ivabradine; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Retrospective Studies; Stroke Volume; Ventricular Function, Left | 2018 |
Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry.
Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Chronic Disease; Cross-Sectional Studies; Female; Furosemide; Guideline Adherence; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Netherlands; Practice Guidelines as Topic; Registries; Renin-Angiotensin System; Sodium Potassium Chloride Symporter Inhibitors; Spironolactone; Stroke Volume | 2019 |
Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study.
Topics: Adult; Age Factors; Aged; Anti-Arrhythmia Agents; Benzazepines; Chronic Disease; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Proportional Hazards Models; Treatment Outcome | 2013 |
The cost effectiveness of ivabradine in the treatment of chronic heart failure from the U.K. National Health Service perspective.
Topics: Anti-Arrhythmia Agents; Benzazepines; Chronic Disease; Cost-Benefit Analysis; Drug Costs; Heart Failure; Heart Rate; Hospital Costs; Humans; Ivabradine; Kaplan-Meier Estimate; Markov Chains; Models, Economic; Quality of Life; Quality-Adjusted Life Years; State Medicine; Time Factors; Treatment Outcome; United Kingdom | 2014 |
[Cost-effectiveness and budget impact of ivabradine in heart failure therapy].
Topics: Benzazepines; Chronic Disease; Cost-Benefit Analysis; Female; Follow-Up Studies; Heart Failure; Humans; Italy; Ivabradine; Male; Markov Chains; Middle Aged; Quality-Adjusted Life Years | 2014 |
Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece.
Topics: Benzazepines; Cardiovascular Agents; Chronic Disease; Cost-Benefit Analysis; Greece; Heart Failure; Humans; Ivabradine; Length of Stay; Markov Chains; Quality-Adjusted Life Years | 2014 |
Characterizing patients with chronic heart failure in community care after hospitalization: a potential role for ivabradine.
Topics: Acute Disease; Aged; Aged, 80 and over; Benzazepines; Bisoprolol; Cardiovascular Agents; Chronic Disease; Clinical Protocols; Drug Utilization; Female; Heart Failure; Hospitalization; Humans; Ivabradine; Male; Medication Therapy Management; Middle Aged; Retrospective Studies; United Kingdom | 2015 |
Ivabradine approved for stable chronic heart failure.
Topics: Benzazepines; Cardiovascular Agents; Chronic Disease; Drug Approval; Heart Failure; Humans; Ivabradine; United States; United States Food and Drug Administration | 2015 |
Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Asia; Australia; Benzazepines; Canada; Cardiovascular Agents; Chronic Disease; Europe; Female; Guideline Adherence; Heart Failure; Humans; Ivabradine; Longitudinal Studies; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic; Prospective Studies; Stroke Volume; Surveys and Questionnaires | 2016 |
Letter by Melgari et al Regarding Article, "Ivabradine: Role in the Chronic Heart Failure Armamentarium".
Topics: Benzazepines; Cardiovascular Agents; Chronic Disease; Heart Failure; Heart Rate; Humans; Ivabradine; Treatment Outcome | 2016 |
Impact of Ivabradine on Inflammatory Markers in Chronic Heart Failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Benzazepines; Biomarkers; Cardiovascular Agents; Chronic Disease; Comorbidity; Cytokines; Echocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Inflammation Mediators; Ivabradine; Male; Middle Aged; Quality of Life; Risk Factors; Treatment Outcome | 2016 |
Comments on the 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.
Topics: Acute Disease; Adrenergic beta-Antagonists; Algorithms; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiac Resynchronization Therapy; Cardiovascular Agents; Chronic Disease; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Early Medical Intervention; Echocardiography; Europe; Extracorporeal Membrane Oxygenation; Heart Failure; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Natriuretic Peptides; Practice Guidelines as Topic; Spain; Stroke Volume; Tetrazoles; Valsartan | 2016 |
[Regulatory Adaptive Status in Assessment of Efficacy of Pharmacotherapy and Prognostication of Complications in Functional Class III Chronic Heart Failure].
Topics: Aged; Benzazepines; Cardiovascular Agents; Chronic Disease; Echocardiography; Exercise Test; Female; Heart Failure; Humans; Hypertension; Ivabradine; Male; Metoprolol; Middle Aged; Quinapril; Random Allocation; Spironolactone; Tetrahydroisoquinolines; Treatment Outcome; Ventricular Function, Left | 2016 |
Angina: Ivabradine for treatment of stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Anti-Arrhythmia Agents; Atenolol; Benzazepines; Chronic Disease; Drug Therapy, Combination; Exercise Tolerance; Heart Rate; Humans; Ivabradine; Treatment Outcome | 2009 |
Ivabradine and outcomes in chronic heart failure.
Topics: Benzazepines; Bundle-Branch Block; Cardiovascular Agents; Chronic Disease; Heart Failure; Heart Rate; Humans; Ivabradine; Patient Selection; Randomized Controlled Trials as Topic; Sinoatrial Node; Treatment Outcome | 2010 |
Ivabradine and outcomes in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cardiovascular Agents; Chronic Disease; Heart Failure; Heart Rate; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Heart rate decrease: a new paradigm in the treatment of heart failure. Insights from the SHIFT study.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Benzazepines; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Evidence-Based Medicine; Heart Failure; Heart Rate; Humans; Ivabradine; Treatment Outcome | 2011 |
Limited role for ivabradine in the treatment of chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Arrhythmias, Cardiac; Benzazepines; Cardiotonic Agents; Chronic Disease; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Patient Selection; Stroke Volume; Ventricular Dysfunction, Left | 2011 |
[The SHIFT study: a shift in a correct direction].
Topics: Anti-Arrhythmia Agents; Benzazepines; Chronic Disease; Clinical Protocols; Cyclic Nucleotide-Gated Cation Channels; Heart Failure; Heart Rate; Humans; Ivabradine; Practice Patterns, Physicians' | 2012 |
[Chronic heart failure therapy: where we are and where we are going to].
Topics: Algorithms; Amides; Benzazepines; Chronic Disease; Fumarates; Heart Failure; Heart Rate; Humans; Ivabradine | 2012 |
[Effect of ivabradin on heart rate, left ventricular function a NT-proBNP concentration in patients with systolic chronic heart failure--case reports].
Topics: Adult; Aged; Benzazepines; Chronic Disease; Cyclic Nucleotide-Gated Cation Channels; Female; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Male; Natriuretic Peptide, Brain; Peptide Fragments; Ventricular Function, Left; Ventricular Remodeling | 2012 |
If at first you don't succeed try ... a new target in the treatment of angina.
Topics: Angina Pectoris; Benzazepines; Chronic Disease; Humans; Ion Channels; Ivabradine | 2005 |
[Ivabradine--a medical alternative for patients with chronic stable angina pectoris].
Topics: Angina Pectoris; Benzazepines; Chronic Disease; Humans; Ivabradine | 2006 |
Heart failure management. Interview with Karl Swedberg.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Benzazepines; Benzimidazoles; Biphenyl Compounds; Cardiac Output, Low; Chronic Disease; Defibrillators, Implantable; Humans; Ivabradine; Practice Guidelines as Topic; Tetrazoles; Ventricular Dysfunction, Left | 2007 |